SSTR3 is a G protein-coupled receptor that functions as a receptor for somatostatin-14 and -28, mediating inhibition of adenylyl cyclase through pertussis toxin-sensitive Gi proteins 1. The receptor plays critical roles in negatively regulating hormone release and cell proliferation, making it a therapeutic target for neuroendocrine tumors 1. SSTR3 localizes to primary cilia through ciliary localization sequences in its C-terminal tail and third intracellular loop, where it functions as a specialized signaling compartment alongside other GPCRs 2. Within cilia, SSTR3 undergoes regulated ubiquitin-mediated retrieval via the BBSome-TOM1L2 complex to enable appropriate signal transduction 3. Clinically, SSTR3 expression is elevated in non-functioning pituitary neuroendocrine tumors (NF-PitNETs) and pancreatic neuroendocrine tumors (Pan-NETs), which respond poorly to conventional somatostatin analogs targeting SSTR2 and SSTR5 45. Novel SSTR3-selective agonists like ITF2984 demonstrate superior antiproliferative and proapoptotic effects in these tumor types, reducing cell proliferation by 40.8% and increasing apoptosis by 41.4% in NF-PitNETs 4. These findings support SSTR3-targeted therapies as promising alternatives for NETs with high SSTR3 expression 5.